Literature DB >> 7850784

Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene.

J Gao1, J G Naglich, J Laidlaw, J M Whaley, B R Seizinger, N Kley.   

Abstract

The human von Hippel-Lindau disease (VHL) gene has recently been identified and, based on the nucleotide sequence of a partial cDNA clone, has been predicted to encode a novel protein with as yet unknown functions [F. Latif et al., Science (Washington DC), 260: 1317-1320, 1993]. The length of the encoded protein and the characteristics of the cellular expressed protein are as yet unclear. Here we report the cloning and characterization of a mouse gene (mVHLh1) that is widely expressed in different mouse tissues and shares high homology with the human VHL gene. It predicts a protein 181 residues long (and/or 162 amino acids, considering a potential alternative start codon), which across a core region of approximately 140 residues displays a high degree of sequence identity (98%) to the predicted human VHL protein. High stringency DNA and RNA hybridization experiments and protein expression analyses indicate that this gene is the most highly VHL-related mouse gene, suggesting that it represents the mouse VHL gene homologue rather than a related gene sharing a conserved functional domain. These findings provide new insights into the potential organization of the VHL gene and nature of its encoded protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850784

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice.

Authors:  J R Gnarra; J M Ward; F D Porter; J R Wagner; D E Devor; A Grinberg; M R Emmert-Buck; H Westphal; R D Klausner; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 2.  The molecular basis of von Hippel-Lindau disease.

Authors:  O Iliopoulos; W G Kaelin
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

3.  Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.

Authors:  S Lee; D Y Chen; J S Humphrey; J R Gnarra; W M Linehan; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

Review 4.  Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms.

Authors:  T Hsu
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

5.  Recessive oncogenes: current status.

Authors:  Xiang Gao; Kenneth V Honn
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

6.  Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.

Authors:  Yves Pastore; Katerina Jedlickova; Yongli Guan; Enli Liu; James Fahner; Henrik Hasle; Jaroslav F Prchal; Josef T Prchal
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

Review 7.  VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.

Authors:  W Kimryn Rathmell; Shufen Chen
Journal:  Expert Rev Anticancer Ther       Date:  2008-01       Impact factor: 4.512

8.  Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.

Authors:  D R Duan; J S Humphrey; D Y Chen; Y Weng; J Sukegawa; S Lee; J R Gnarra; W M Linehan; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

9.  pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.

Authors:  O Iliopoulos; M Ohh; W G Kaelin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

10.  A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.

Authors:  A Schoenfeld; E J Davidowitz; R D Burk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.